ATE535252T1 - Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit - Google Patents
Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheitInfo
- Publication number
- ATE535252T1 ATE535252T1 AT06751930T AT06751930T ATE535252T1 AT E535252 T1 ATE535252 T1 AT E535252T1 AT 06751930 T AT06751930 T AT 06751930T AT 06751930 T AT06751930 T AT 06751930T AT E535252 T1 ATE535252 T1 AT E535252T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- disease
- preventing
- immunogenic fragment
- peptide conjugate
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000863 peptide conjugate Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 4
- 230000002163 immunogen Effects 0.000 abstract 4
- 208000037259 Amyloid Plaque Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003028 elevating effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67788605P | 2005-05-05 | 2005-05-05 | |
| PCT/US2006/016481 WO2006121656A2 (en) | 2005-05-05 | 2006-05-01 | Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE535252T1 true ATE535252T1 (de) | 2011-12-15 |
Family
ID=37019042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06751930T ATE535252T1 (de) | 2005-05-05 | 2006-05-01 | Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7850973B2 (de) |
| EP (2) | EP1879613B1 (de) |
| JP (1) | JP2008540417A (de) |
| KR (1) | KR20080005260A (de) |
| CN (1) | CN101171031B (de) |
| AT (1) | ATE535252T1 (de) |
| AU (1) | AU2006246382A1 (de) |
| BR (1) | BRPI0610093A2 (de) |
| CA (1) | CA2607868A1 (de) |
| IL (1) | IL186793A0 (de) |
| MX (1) | MX2007013825A (de) |
| NO (1) | NO20076239L (de) |
| NZ (1) | NZ562434A (de) |
| RU (1) | RU2406529C2 (de) |
| WO (1) | WO2006121656A2 (de) |
| ZA (1) | ZA200708635B (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| CA2590337C (en) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
| EP1963363A2 (de) | 2005-11-30 | 2008-09-03 | Abbott Laboratories | Verfahren zur herstellung rekombinanter formen von humanem beta-amyloid-protein und verwendung dieser proteine |
| CN101506236B (zh) | 2005-11-30 | 2012-12-12 | 雅培制药有限公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
| DK1954718T3 (en) | 2005-11-30 | 2014-12-15 | Abbvie Inc | Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies, |
| WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US20090175847A1 (en) * | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| CL2008001742A1 (es) * | 2007-06-12 | 2008-11-21 | Ac Immune Sa | Anticuerpo monoclonal que reconoce un epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos; polinucleotido que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados a proteinas amiloides. |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| EP2020602A1 (de) * | 2007-08-02 | 2009-02-04 | Araclon Biotech | Hochempfindliche Immuntests und Kits zur Bestimmung biologisch interessanter Peptide und Proteine |
| DK2238166T3 (da) | 2007-10-05 | 2014-01-27 | Ac Immune Sa | Anvendelse af et anti-amyloid-beta-antistof ved øjensygdomme |
| ITMI20071975A1 (it) * | 2007-10-12 | 2009-04-13 | Fond I R C C S Istituto Neur O | Prodotti e loro uso per la diagnosi prevenzione e-o cura di patologie umane e-o animali caraterizzate dalla anomala deposizione di sostanza b-amiloide e-o similamiloide in organi e tesstui umani e-o animali e metodo di screening per la determinazione |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| WO2009054537A1 (ja) | 2007-10-25 | 2009-04-30 | Kagoshima University | アミロイドβペプチドのミミック分子を用いたペプチドワクチン |
| JP5722770B2 (ja) * | 2008-07-01 | 2015-05-27 | デ スタート デル ネダーランデン、フェルト．ドール デ ミニスター ファン フォルクスヘーゾンドハイド、フェルジイン アン スポルト | アミロイド折りたたみ中間体に対するワクチン |
| JP2011527681A (ja) * | 2008-07-08 | 2011-11-04 | メルク・シャープ・エンド・ドーム・コーポレイション | アルツハイマー病治療用ワクチン |
| EP2149380A1 (de) * | 2008-07-29 | 2010-02-03 | Medivet Pharma, S.L. | Tierärztliche Immuntherapiezusammensetzung für altersbedingte kognitive Dysfunktion |
| WO2010040175A1 (en) * | 2008-10-06 | 2010-04-15 | Commonwealth Scientific And Industrial Research Organisation | Amyloid-beta peptide crystal structure |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| EP2258398A1 (de) * | 2009-05-26 | 2010-12-08 | Araclón Biotech, S. L. | Albumin/Amyloidpeptid-Konjugate und deren Verwendungen |
| CA3239368A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| JP2013521233A (ja) | 2010-02-25 | 2013-06-10 | ヤンセン アルツハイマー イミュノセラピー | Ａβを標的とする免疫療法のＰＥＴモニタリング |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| CA2806909C (en) | 2010-07-30 | 2019-12-17 | Ac Immune S.A. | Safe and functional humanized antibodies |
| JP6147665B2 (ja) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | アミロイドベータ結合タンパク質 |
| US20120328605A1 (en) * | 2010-10-27 | 2012-12-27 | Daniel Larocque | Compositions and uses |
| WO2012072611A1 (de) * | 2010-11-29 | 2012-06-07 | Philipps-Universität Marburg | SYNTHETISCHE LIGANDEN FÜR HUMANE ANTI-Aβ-ANTIKÖRPER |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| US9610326B2 (en) | 2011-10-17 | 2017-04-04 | The Board Of Trustees Of The Leland Stanford Junior University | Amyloid beta peptides as therapy for multiple sclerosis |
| CA2945052C (en) * | 2014-04-15 | 2023-05-02 | Griffith University | Group a streptococcus vaccine |
| WO2016007414A1 (en) | 2014-07-08 | 2016-01-14 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
| EP3334453A4 (de) | 2015-08-13 | 2019-02-06 | New York University | Antikörperbasierte, für das verkürzte asp421-epitop von tau spezifische moleküle und deren verwendungen in der diagnose und behandlung von tauopathie |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| US20210214406A1 (en) * | 2016-04-14 | 2021-07-15 | Tao Health Life Pharma Co., Ltd. | Amylospheroid (aspd)-like structure and pharmaceutical composition |
| KR101898623B1 (ko) | 2016-11-10 | 2018-09-13 | 주식회사 브레인숲 | 종이 완구블록 |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| EA202091012A1 (ru) | 2017-10-25 | 2020-08-27 | Янссен Фармасьютикалз, Инк. | Композиции фосфорилированных тау-пептидов и их применения |
| RU2679059C1 (ru) * | 2018-04-17 | 2019-02-05 | Александр Олегович Морозов | Пептид и способ лечения болезни альцгеймера |
| RU2679080C1 (ru) * | 2018-04-17 | 2019-02-05 | Александр Олегович Морозов | Пептид и способ лечения болезни альцгеймера |
| IL285163B2 (en) | 2019-02-08 | 2025-05-01 | Ac Immune Sa | Method for safe administration of phosphorylated tau peptide vaccine |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング，インコーポレイテッド | ガレクチン－３を遮断することにより炎症性疾患を処置する方法 |
| CN116063382B (zh) * | 2022-11-17 | 2024-11-05 | 山东大学 | 一种具有三阶非线性光学性能的多肽材料及其制备方法与应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5494808A (en) | 1994-09-15 | 1996-02-27 | Merck & Co., Inc. | Defined medium OMPC fermentation process |
| US6905686B1 (en) * | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| JP3854481B2 (ja) * | 2000-11-17 | 2006-12-06 | 三菱重工業株式会社 | 湿式排煙脱硫装置、及び、湿式排煙脱硫方法 |
| DK1397380T3 (da) * | 2001-06-20 | 2007-05-07 | Univ Ramot | Multipelt antigent peptid, der udviser flere kopier af en epitop af et plaquedannende polypeptid, og fremgangmåder til anvendelse deraf |
| MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| WO2004069182A2 (en) * | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
| US20070134762A1 (en) * | 2003-12-17 | 2007-06-14 | Arumugham Rasappa G | Immunogenic peptide carrier conjugates and methods of producing same |
-
2006
- 2006-05-01 EP EP06751930A patent/EP1879613B1/de not_active Not-in-force
- 2006-05-01 CA CA002607868A patent/CA2607868A1/en not_active Abandoned
- 2006-05-01 MX MX2007013825A patent/MX2007013825A/es active IP Right Grant
- 2006-05-01 AT AT06751930T patent/ATE535252T1/de active
- 2006-05-01 JP JP2008510087A patent/JP2008540417A/ja active Pending
- 2006-05-01 EP EP10181823A patent/EP2269633A1/de not_active Withdrawn
- 2006-05-01 RU RU2007145052/10A patent/RU2406529C2/ru not_active IP Right Cessation
- 2006-05-01 NZ NZ562434A patent/NZ562434A/en not_active IP Right Cessation
- 2006-05-01 BR BRPI0610093-7A patent/BRPI0610093A2/pt not_active IP Right Cessation
- 2006-05-01 CN CN2006800153890A patent/CN101171031B/zh not_active Expired - Fee Related
- 2006-05-01 WO PCT/US2006/016481 patent/WO2006121656A2/en active Application Filing
- 2006-05-01 KR KR1020077025682A patent/KR20080005260A/ko not_active Ceased
- 2006-05-01 US US11/919,897 patent/US7850973B2/en not_active Expired - Fee Related
- 2006-05-01 AU AU2006246382A patent/AU2006246382A1/en not_active Abandoned
-
2007
- 2007-10-10 ZA ZA2007/08635A patent/ZA200708635B/en unknown
- 2007-10-18 IL IL186793A patent/IL186793A0/en unknown
- 2007-12-04 NO NO20076239A patent/NO20076239L/no not_active Application Discontinuation
-
2010
- 2010-11-08 US US12/907,493 patent/US20110052611A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007013825A (es) | 2008-01-18 |
| US20110052611A1 (en) | 2011-03-03 |
| WO2006121656A3 (en) | 2007-01-04 |
| RU2007145052A (ru) | 2009-06-10 |
| CA2607868A1 (en) | 2006-11-16 |
| NZ562434A (en) | 2010-04-30 |
| US20090098155A1 (en) | 2009-04-16 |
| IL186793A0 (en) | 2008-02-09 |
| ZA200708635B (en) | 2008-10-29 |
| KR20080005260A (ko) | 2008-01-10 |
| BRPI0610093A2 (pt) | 2008-12-09 |
| JP2008540417A (ja) | 2008-11-20 |
| CN101171031B (zh) | 2011-09-28 |
| EP1879613B1 (de) | 2011-11-30 |
| AU2006246382A1 (en) | 2006-11-16 |
| WO2006121656A2 (en) | 2006-11-16 |
| NO20076239L (no) | 2008-01-30 |
| EP1879613A2 (de) | 2008-01-23 |
| EP2269633A1 (de) | 2011-01-05 |
| CN101171031A (zh) | 2008-04-30 |
| RU2406529C2 (ru) | 2010-12-20 |
| US7850973B2 (en) | 2010-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE535252T1 (de) | Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit | |
| ES2407429T3 (es) | Vacuna terapéurica | |
| AR024074A1 (es) | FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS. | |
| IL164643A (en) | Peptides, immunogenic compositions containing them and use thereof for the preparation of medicaments for the treatment of alzheimer's disease | |
| NO20071267L (no) | Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer | |
| MY158903A (en) | Antibodies specific for the protofibril form of beta-amyloid protein | |
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| MX349481B (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. | |
| MXPA05008156A (es) | Inmunizacion activa para generar anticuerpos para beta-a soluble. | |
| MXPA05011110A (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. | |
| EA200601761A1 (ru) | Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| RU2009102815A (ru) | Полипептиды из neisseria meningitidis | |
| ATE369380T1 (de) | Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten | |
| RU2009148539A (ru) | Способ лечения болезни альцгеймера | |
| ATE551060T1 (de) | Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen | |
| JP2009520758A5 (de) | ||
| UA99094C2 (ru) | Способ лечения пациента с системной красной волчанкой | |
| EA200800397A1 (ru) | Композиции тизанидина и способы лечения с применением композиций | |
| JP2006506942A5 (de) | ||
| EA201300421A1 (ru) | Комбинированная терапия для лечения инфекции hcv | |
| MA27699A1 (fr) | Vaccin contre vhc | |
| BR0213941A (pt) | Arranjos de antìgeno para o tratamento de doença óssea | |
| JP2017508006A5 (de) | ||
| WO2006138745A3 (en) | Therapeutic peptides and vaccines |